New diagnostic tools in male LUTS

**Location:** Room 14a (ICM, Level 1)

**Chairs:** M. Oelke, Hannover (DE)
A. Tubaro, Rome (IT)

**Aims and objectives of this presentation**
New diagnostic tools are being developed to allow us better screening and patient selection. These tools are being scrutinized in this session.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**98**

**Lower urinary tract symptoms, depression and adverse life events: Data from the European Male Ageing Study**
**By:** Cocci A.1, Gacci M.1, Drake M.2, Castellini G.3, Ricca V.4, Forti G.1, Wu F.5, Maggi M.3

**Institutes:** 1University of Florence, Dept. of Urology, Florence, Italy, 2University of Bristol, Dept. of Urology, Bristol, United Kingdom, 3Sexual Medicine and Andrology Unit, Dept. of Experimental, Clinical and Biomedical Sciences, Florence, Italy, 4Psychiatric Unit, University of Florence, Dept. of Neuropsychiatric Sciences, Florence, Italy, 5Andrology Research Unit, Endocrinology and Diabetes Research Group, Institute of Human Development, Manchester, United Kingdom

---

**99**

**Correlation between uroflowmetry and a new visual pictogram in patients with lower urinary tract symptoms: Analogical uroflowmetry (ANUF)**
**By:** Rogel R., Lorenzo L., Avaroques A., Lujan S., Broseta E., Boronat F.

**Institutes:** Hospital Universitari I Politècnic La Fe, Dept. of Urology, Valencia, Spain

---

**100**

**A prostate cancer risk polymorphism (rs12500426) of the PDLIM5 gene is a strong determinant of age related benign prostate hypertrophy**
**By:** Audouin M.1, Barkatz J.1, Cox D.8, Roupret M.2, Cormier L.3, Valeri A.4, Azzouzi A-R.5, Ondet V.6, Gaffory C.7, Cancel-Tassin G.7, Cussenot O.1

**Institutes:** Assistance Publique-Hopitaux De Paris, Tenon Hospital, Dept. of Urology, Paris, France, Assistance Publique-Hopitaux De Paris, Pitie-Salpetriere Hospital, Dept. of Urology, Paris, France, CHU Dijon, Dept. of Urology, Dijon, France, CHU Brest, Dept. of Urology, Brest, France, CHU Angers, Dept. of Urology, Angers, France, UPMC Univ Paris 06, GRC N°5 ONCOTYPE-URO, Paris, France, CeRePP, GRC N°5 ONCOTYPE-URO, Paris, France, INSERM, U1052, Lyon, France

---

**101**

**Developing a clinical nomogram for detection of bladder outlet obstruction in non-neurogenic male patients with overactive bladder symptoms**
**By:** Chen W.J., Fan Y.H., Lin A.T.L., Chen K.K.

**Institutes:** Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan

---

**102**

**Methylation of CpG islands in promoter of type 2 5-α reductase and implications of finasteride resistance for BPH therapy**
**By:** Jin S., Fan D., Liu Z., Sun J., Xing N., Niu Y.

**Institutes:** Beijing Chao-Yang Hospital, Dept. of Urology, Beijing, China

---

**103**

**Serum vitamin D level in benign prostatic hyperplasia and hypogonadism has different correlations according to metabolic status**
**By:** Park M.G.1, Dae Yeon C.1, Jeong Kyun Y.1, Jeong Woo L.2, Sung Yong C.3, Min Chul C.3

**Institutes:** Inje University, Seoul Paik Hospital, Dept. of Urology, Seoul, South Korea, Dongguk University, Dept. of Urology, Seoul, South Korea, Seoul University, Dept. of Urology, Seoul, South Korea
Prospective evaluation of quality of information provided to patients before a transurethral resection of the prostate
By: Dominique I., Meyer V., Terrier J-E., Badet L., Paparel P., Ruffion A., Champetier D.
Institutes: CHU Lyon Sud, Dept. of Urology, Rhones Alpes, Pierre Benite, France, CHU Edouard Herriot, Dept. of Urology, Rhones Alpes, Lyon, France

Impact of treatment with statin on prostate volume and lower urinary tract symptoms: 3-Year follow-up
By: Han J-Y., Jeong S.C., Lee S.S., Park S-W., Chung M.K.
Institutes: Pusan National University Hospital, Dept. of Urology, Yangsan, South Korea

Impairment of autophagy in prostatic inflammation
By: Vecchione A., De Nunzio C., Cirombella R., Lombardo R., Stoppacciaro A., Tubaro A.
Institutes: Sant' Andrea Hospital - Sapienza University, Dept. of Molecular Pathology, Rome, Italy, Sant' Andrea Hospital - Sapienza, Dept. of Urology, Rome, Italy, Sant' Andrea Hospital 'La Sapienza', Dept. of Molecular Pathology, Rome, Italy, Sant' Andrea Hospital 'La Sapienza', Dept. of Urology, Rome, Italy

Intravesical prostatic protrusion can predict postoperative outcomes in patients with benign prostatic hyperplasia who undergo trans urethral resection of prostate (TURP)
By: Nur Budaya T., Daryanto B., Soetojo S.
Institutes: Dr. Soetomo Hospital, Faculty of Medicine Airlangga University, Dept. of Urology, Surabaya, Indonesia, Dr. Saiful Anwar Hospital, Faculty of Medicine Brawijaya University, Dept. of Urology, Malang, Indonesia

The relationship between body mass index and benign prostate hyperplasia in large scale community based cohort
By: Choi S.M., Yoon S., Jeo S.U., Kam S.C., Hwa J.S., Chung K.H., Hyun J.S.
Institutes: Gyeongsang National University Hospital, Dept. of Urology, Jinju, South Korea

A preoperative nomogram to predict functional outcomes of Greenlight® XPS 180 W photoselective vaporization of the prostate
By: Peyronnet B., Hupertan V., Pradère B., Phé V., Zorn K., Rouprêt M., Misrai V.
Institutes: CHU Rennes, Dept. of Urology, Rennes, France, Bichat Hospital, Dept. of Urology, Paris, France, CHU Tours, Dept. of Urology, Tours, France, Pitie Salpetriere Hospital, Dept. of Urology, Paris, France, McGill University, Dept. of Urology, Montreal, France, Clinique Pasteur, Dept. of Urology, Toulouse, France